Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$485.42 USD

485.42
904,979

+3.15 (0.65%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Veeva Systems' (VEEV) Latest Launches to Enhance Workflow

by Zacks Equity Research

Veeva Systems' (VEEV) new offerings are expected to aid the marketing and field teams with more accurate and actionable insights into patient and HCP touchpoints.

McKesson (MCK) Stock Moves -1.99%: What You Should Know

by Zacks Equity Research

McKesson (MCK) closed the most recent trading day at $342, moving -1.99% from the previous trading session.

Merit Medical (MMSI) Launches New Soft Tissue Biopsy System

by Zacks Equity Research

Merit Medical's (MMSI) launch of the TEMNO Elite Soft Tissue Biopsy System will boost its portfolio of biopsy devices.

Zacks.com featured highlights include Hyatt Hotels, McKesson and Carlsberg

by Zacks Equity Research

Hyatt Hotels, McKesson and Carlsberg are part of Zacks Screen of the Week article.

PacBio's (PACB) New Method for TR Profiling Now Available

by Zacks Equity Research

PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.

3 Reasons to Hold Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips

by Zacks Equity Research

The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.

Here's Why Investors Should Hold Exact Sciences (EXAS) Stock

by Zacks Equity Research

Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.

Stryker (SYK) Launches Q Guidance System for Spine Applications

by Zacks Equity Research

Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during guided spine surgery following its launch.

3 Reasons to Retain CONMED (CNMD) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Swayta Shah headshot

3 Stocks With Upgraded Broker Ratings for Impressive Returns

by Swayta Shah

As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select Hyatt Hotels (H), McKesson (MCK) and Carlsberg (CABGY) as these have seen rating upgrades recently.

PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows

by Zacks Equity Research

PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay

by Zacks Equity Research

Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain momentum from robust medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.

The Zacks Analyst Blog Highlights McKesson, Corteva, Atmos Energy and National Fuel Gas

by Zacks Equity Research

McKesson, Corteva, Atmos Energy and National Fuel Gas are part of the Zacks top Analyst Blog.

3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why Investors Should Hold Myriad Genetics (MYGN) Now

by Zacks Equity Research

Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.

ResMed (RMD) Gains on Product Uptake Even as Expenses Rise

by Zacks Equity Research

The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.

Here's Why You Should Hold on to OPKO Health (OPK) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

Snehadri Nag headshot

4 Top-Ranked Defensive Stocks to Buy Amid Market Swings

by Snehadri Nag

Here we mention four defensive stocks, namely Corteva (CTVA), Atmos Energy, National Fuel Gas Company and McKesson with strong prospects to beat the market whims.

McKesson (MCK) Stock Moves -1.06%: What You Should Know

by Zacks Equity Research

McKesson (MCK) closed at $343.27 in the latest trading session, marking a -1.06% move from the prior day.

Derek Lewis headshot

3 Medical Stocks Displaying Remarkable Relative Strength in 2022

by Derek Lewis

In addition to favorable price action, all three carry a strong growth profile, making them appear even more enticing.

Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod

by Zacks Equity Research

Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.